[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cosgrove Delos M., a director of Hims & Hers Health, Inc. (HIMS), was granted 3,656 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of Class A Common Stock, with an indicated price of $0 per unit. Following the grant, the reporting person beneficially owns 3,656 shares on a direct basis.

The RSUs vest subject to continuous service on the earlier of the company’s 2026 annual meeting of stockholders or June 15, 2026, so the award is structured as a near-term retention/compensation award that will convert into ordinary shares if service conditions are met.

Positive

• 3,656 RSUs granted to a director aligns the reporting person’s interests with long-term shareholder value by tying compensation to company equity
• Near-term vesting schedule (earlier of 2026 annual meeting or June 15, 2026) supports retention through the next shareholder meeting cycle

Negative

• Potential dilution when 3,656 RSUs convert into Class A Common Stock upon vesting
• No cash consideration ($0 price) means the company will issue shares rather than receive proceeds

Insights

Corporate Governance Expert

TL;DR: Routine director compensation via RSUs, structured for near-term vesting to retain board service.

This Form 4 reports a standard equity grant to a director: 3,656 RSUs that convert one-for-one into Class A common stock and vest at the earlier of the 2026 annual meeting or June 15, 2026, subject to continuous service. Such grants are commonly used to align director incentives with shareholders and to encourage continued board participation through the next annual meeting cycle. The direct ownership form indicates the recipient holds beneficial title to the award rather than through an indirect vehicle.

Securities Analyst

TL;DR: Small, non-cash equity issuance; immaterial to capital structure but will increase outstanding shares if settled.

The grant size (3,656 RSUs) is modest relative to typical public-company share counts and carries a stated price of $0, indicating no cash was exchanged. If and when the RSUs vest and convert to Class A shares, they will increase the count of outstanding shares by the same amount, producing a small dilution. There is no cash exercise or purchase price, and vesting is time-based through mid-2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cosgrove Delos M.

(Last) (First) (Middle)

2269 CHESTNUT STREET, #523

(Street)

SAN FRANCISCO, CA 94123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		3,656		(1)	(1)	Class A Common Stock	3,656	$0	3,656	D

Explanation of Responses:

1. The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. Subject to continuous service, the RSUs will vest on the earlier of (a) the date of the 2026 annual meeting of stockholders or (b) June 15, 2026.

Remarks:

	/s/ Alexandra Cotter Wilkins, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who received the RSU grant reported on the Form 4 for HIMS?

The reporting person is Cosgrove Delos M., identified as a director of Hims & Hers Health, Inc.

How many RSUs were granted to the reporting person (HIMS)?

The grant was for 3,656 Restricted Stock Units (RSUs), each representing a contingent right to one share of Class A Common Stock.

When was the RSU transaction for HIMS reported to have occurred?

The transaction date listed is 08/06/2025.

When do the RSUs vest according to the Form 4?

The RSUs vest subject to continuous service on the earlier of the 2026 annual meeting of stockholders or June 15, 2026.

What is the economic cost to the reporting person for these RSUs?

The Form 4 shows a $0 price for the RSUs, indicating no cash purchase price was paid.